Knoll Capital Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Knoll Capital Management’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-101	Closed	-$696K	–	20
2019 Q3	$696K	Sell	101 -42	-29%	-$337K	0.64%	19
2019 Q2	$1.51M	Hold	143	–	–	1.24%	13
2019 Q1	$1.68M	Sell	143 -3	-2%	-$34.9K	1.28%	13
2018 Q4	$1.43M	Hold	146	–	–	1.63%	8
2018 Q3	$2.88M	Hold	146	–	–	2.44%	7
2018 Q2	$2.5M	Buy	+146	New	+$1.69M	2.12%	8
2016 Q3	–	Sell	-35	Closed	-$224K	–	20
2016 Q2	$224K	Sell	35 -10	-22%	-$75.6K	0.07%	20
2016 Q1	$320K	Hold	45	–	–	0.13%	19
2015 Q4	$495K	Hold	45	–	–	0.18%	17
2015 Q3	$483K	Hold	45	–	–	0.21%	16
2015 Q2	$654K	Hold	45	–	–	0.21%	15
2015 Q1	$612K	Hold	45	–	–	0.18%	13
2014 Q4	$377K	Hold	45	–	–	0.15%	12
2014 Q3	$559K	Hold	45	–	–	0.22%	10
2014 Q2	$633K	Hold	45	–	–	0.28%	10
2014 Q1	$746K	Buy	+45	New	+$843K	0.39%	10

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

RCG

Rock Creek Group Washington, District of Columbia $994M AUM 11.29% 1-Year Est. Return

Knoll Capital Management's GLMD Position: Q4 2019 in Review

Knoll Capital Management sold out of Galmed Pharmaceuticals (GLMD) in Q4 2019, closing a stake of 101 shares — an estimated $696K sold.

Knoll Capital Management first reported a position in GLMD in Q1 2014 and held it in 16 quarters. The position peaked at $2.88M in Q3 2018. 28 funds tracked by Wall St. Rank hold GLMD as of Q4 2019.

Knoll Capital Management reported no remaining Galmed Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Knoll Capital Management sold 101 Galmed Pharmaceuticals shares in Q4 2019, an estimated $696K.
Knoll Capital Management first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 16 quarters.
Knoll Capital Management's Galmed Pharmaceuticals position peaked at $2.88M in Q3 2018.
28 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2019.

Based on Knoll Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.